DEAL WATCH: Biosimilars, Biosimilars and More Biosimilars

It has been a busy week so far for biosimilar developers, with multiple collaboration and commercialization deals announced.

First, on November 4, Henlius and Ascentage Pharma announced that they entered into a collaboration to conduct clinical trials of the combination therapy for oncology using Henlius’s rituximab biosimilar, HLX01, which was approved and launched in China earlier this year, and Ascentage’s APG-2575, a proprietary orally administered Bcl-2 selective inhibitor.